Quebec · CCAA

Application for an Extension Order up to and including January 29, 2027

Application / notice of application · 25 September 2026

AI summary

A plain-English summary drawn only from this filing: what it is, why it matters, and the parties, amounts and dates it turns on.

What we verified from this filing1 verified

secured creditorsnote: Outstanding balance not stated on these pages. Also described as 'Sagard, as secured creditor', to whom any residual amount at the end of the estate administration will be distributed, after a provision for an eventual bankruptcy of the Debtors. A distribution of net proceeds to the secured creditors has already been made (para 37e); amount not stated. · page: 2 · debtor: Initial Debtors (Valeo Pharma Inc., VPI Pharmaceuticals Inc., Valeo Pharma Corp.) · creditor: Sagard Healthcare Royalty Partners (Delaware), LP (Interim Lender) · currency: USD · security: Interim Lender Charge: super-priority charge and security over all assets of each Initial Debtor, increased on Oct 11, 2024 from CA$1,200,000 to CA$8,000,000 (charge ceiling, not a balance); authorized interim borrowing of up to US$750,000 initially, increased to up to US$5,000,000 (facility limits, not balances)